Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Avsola is a prescription biologic containing infliximab-axxq, a tumor necrosis factor blocker and biosimilar to infliximab. It is approved for Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis under labeled age and disease criteria. Avsola is supplied as a 100 mg vial for intravenous infusion after reconstitution and dilution.
read more about avsola ...Infliximab-axxq binds with high affinity to soluble and transmembrane tumor necrosis factor alpha and blocks interaction with TNF receptors. TNF alpha participates in inflammatory signaling linked to intestinal, joint, and skin disease. Blocking this pathway reduces inflammatory activity associated with the conditions listed in the prescribing information.
Avsola is approved for adults with Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis under labeled criteria. Pediatric use includes moderately to severely active Crohn disease and ulcerative colitis in patients age 6 and older who have had an inadequate response to conventional therapy.
Avsola is infused intravenously over at least two hours. Crohn disease and ulcerative colitis regimens use 5 mg per kg at weeks 0, 2, and 6, followed by every 8 weeks. Rheumatoid arthritis starts at 3 mg per kg with methotrexate on the same induction schedule. Ankylosing spondylitis uses maintenance dosing every 6 weeks.
Avsola carries a boxed warning for serious infections and malignancy. Tuberculosis, bacterial sepsis, invasive fungal infections, lymphoma, and hepatosplenic T-cell lymphoma are among the reported risks. Other concerns include hepatitis B reactivation, liver injury, worsening heart failure, blood cell abnormalities, infusion reactions, neurologic disorders, and lupus-like syndrome. Live vaccines are avoided during treatment.
Yes. Avsola contains infliximab-axxq, a monoclonal antibody that binds tumor necrosis factor alpha and blocks its inflammatory activity.
Yes. Avsola is an FDA-approved biosimilar to the reference infliximab product.
Avsola is given by intravenous infusion after reconstitution and dilution. The infusion lasts at least two hours.
Yes. Its boxed warning covers serious infections and malignancy, including tuberculosis, invasive fungal infections, lymphoma, and hepatosplenic T-cell lymphoma.
AVSOLA (infliximab-axxq) Medication Guide. https://www.pi.amgen.com/united_states/avsola/avsola_mg_hcp_english.pdf. Date Accessed September 15, 2026.
AVSOLA (infliximab-axxq) Prescribing Information. https://www.pi.amgen.com/united_states/avsola/avsola_pi_english.pdf. Date Accessed September 15, 2026.
Biosimilar Product Information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Date Accessed September 15, 2026.
DailyMed - AVSOLA (infliximab-axxq) injection, powder, lyophilized, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de34bcb7-b524-45c8-9181-61c6f48d540e. Date Accessed September 15, 2026.
Infliximab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a604023.html. Date Accessed September 15, 2026.